Spectral AI Appoints New CFO David McGuire

Written by Emily J. Thompson, Senior Investment Analyst

Source: seekingalpha

Updated: Apr 08 2026

0mins

MDAI-4.02%

Should l Buy MDAI?

Source: seekingalpha

New CFO Appointment: Spectral AI announced the appointment of David McGuire as CFO effective May 4, 2026, indicating the company's strategic emphasis on financial management with McGuire's over 20 years of finance and accounting experience.
Extensive Industry Background: McGuire most recently served as CAO at Solo Brands and held the positions of deputy CFO and chief accounting officer at EZCORP, where he oversaw financial operations and capital markets activities, suggesting his expertise will positively impact Spectral AI.
Market Reaction: Despite the announcement of the new appointment, Spectral AI's shares fell by 1.20%, reflecting a cautious market sentiment regarding the company's future financial performance, which may affect investor confidence.
Strategic Implications: McGuire's appointment not only enhances the company's financial management capabilities but may also support future capital market activities and strategic initiatives, helping the company maintain its competitive edge in a challenging market.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy MDAI?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on MDAI

Wall Street analysts forecast MDAI stock price to rise

2 Analyst Rating

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 1.990

Low

3.00

Averages

4.50

High

6.00

Current: 1.990

Low

3.00

Averages

4.50

High

6.00

BTIG

Buy

downgrade

$3 -> $2

2025-05-14

Reason

BTIG

Price Target

$3 -> $2

AI Analysis

2025-05-14

downgrade

Buy

Reason

BTIG lowered the firm's price target on Spectral AI to $2 from $3 and keeps a Buy rating on the shares after its Q1 results. The company is appropriately trimming operating spend to preserve cash, though the firm is reducing its price target to reflect a higher share count, the analyst tells investors in a research note. Spectral AI also continues to expect to submit DeepView to the FDA by the end of 2Q25 with approval expected in early FY26, the firm adds.

About MDAI

Spectral AI, Inc. is a predictive artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, with initial applications involving patients with burns. The Company's DeepView platform is a predictive device that offers clinicians an objective and immediate assessment of a wound healing potential prior to treatment or other medical intervention. DeepView platform that combines AI algorithms and multispectral imaging (MSI) imaging for an assessment of wound healing potential. It is non-invasive, non-radiation, non-laser and does not require the use of injectable dye. The DeepView AI- Burn software is used with the DeepView SnapShot imaging device, and it is intended to be used as an adjunctive tool to aid healthcare providers in the assessment of burn wound healing potential by differentiating non-healing from healing burned tissue within an image.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Spectral AI to Showcase DeepView System at American Burn Association Annual Meeting

6 days agoNewsfilter

Event Participation: Spectral AI will showcase its DeepView® System at the American Burn Association Annual Meeting from April 14-17, 2026, in Orlando, Florida, attracting over 2,200 clinicians and researchers, which will enhance the company's influence in the burn care industry.
Product Demonstration: The DeepView System combines multispectral imaging with a proprietary AI algorithm to rapidly assess the healing potential of burn wounds, enabling clinicians to make faster treatment decisions, which is expected to significantly improve patient outcomes and reduce healthcare costs.
FDA Application Progress: Spectral AI submitted its De Novo 510(k) marketing clearance application for the DeepView System to the FDA in June 2025, and if approved, it will further accelerate the product's market entry and strengthen the company's competitive position in medical diagnostics.
Industry Recognition: Spectral AI has been named one of TIME's Top HealthTech Companies of 2025, highlighting its leadership in medical technology innovation and is expected to attract more investor interest in its future growth potential.